Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter and year ended 30th June 2026. Revenue from operations increased by 26% YoY to Rs.2150 Cr. Profit After Tax at Rs. 173 Cr, up 12% YoY. EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24%. The company has started FY27 on a strong note, delivering broad-based growth across its businesses.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about Investor Presentation on Unaudited Financial Results for the quarter ended 30th June, 2026. The presentation highlights a 26% YoY growth in revenue, with key highlights including a 7% YoY growth in India Branded Business, 49% YoY growth in US Formulation, and 33% YoY growth in R&D. The company also reported a 33% YoY growth in PAT, supported by a strong order book.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has submitted its financial results for the quarter ended June 30, 2026, with the Board of Directors approving the consolidated and standalone unaudited financial results along with the Limited Review Report issued by the Statutory Auditors.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 173.07 crore and revenue from operations of Rs. 2,149.71 crore.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, a treatment for chronic idiopathic constipation in adults.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has scheduled a post-results conference call on August 4th to discuss Q1 FY27 unaudited financial results.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited's partner NATCO Pharma Limited receives USFDA tentative approval for Olaparib Tablets, 100 mg and 150 mg. This is the 244th ANDA approval for Alembic, with 224 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received a Warning Letter from the USFDA regarding observations on Informed Consent Form (ICF) in a bioequivalence study. The Company believes the Warning Letter does not impose any restriction on its operations and is coordinating with the Clinical Investigator to submit a response within the stipulated timeline.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about the notice of its 16th Annual General Meeting (AGM) to be held on August 5, 2026, through video conferencing or other audio-visual means. The AGM will consider the business as set out in the notice, including the payment of dividend for the FY 2025-26, if approved. The company has also provided the facility of e-voting through the National Securities Depository Limited (NSDL) for its members.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange regarding the specimen copy of the letter sent to shareholders under Regulation 36(1)(b) of SEBI LODR, and has also announced the 16th Annual General Meeting (AGM) of the company, scheduled to be held on August 5, 2026, through Video Conference facility/ Other Audio Visual Means (VC/OAVM).

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has announced the record date for the payment of dividend for the financial year ended 31st March, 2026, as 29th July, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange regarding Notice of 16th Annual General Meeting to be held on August 05, 2026. The meeting will consider various resolutions including appointment of a director, dividend declaration, and ratification of remuneration to the cost auditors.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended June 30, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication related to notice of loss of equity share certificate, for claiming shares from IEPF Authority, published by the Company on behalf of the registered shareholder in Indian Express (English Edition) and Financial Express (Gujarati Edition) on 7th July, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about the reaffirmation of its credit rating on bank loan facilities and commercial paper by CRISIL Ratings Limited.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received USFDA Final Approval for Dapsone Gel, 5%, a topical treatment for acne vulgaris.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in securities of the Company will remain closed from 1st July, 2026 till 48 hours after the declaration of the Unaudited financial results for the quarter ended 30th June, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about a newspaper publication regarding notice of loss of equity share certificate(s) for claiming shares from IEPF Authority.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, with an estimated market size of US$ 27 million.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has announced a schedule of one-on-one meetings with prominent institutional investors in June 2026. The company's management will engage with HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company Limited on June 22, 23, and 25. These meetings will include both in-person sessions in Mumbai and virtual conferences. Alembic Pharma explicitly stated that no Unpublished Price Sensitive Information will be shared during these interactions. This signifies routine investor relations activity, providing an avenue for management to engage with key stakeholders without disclosing new material information.